

Andreas Barratt-Due

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/195306/publications.pdf>

Version: 2024-02-01

54
papers

3,796
citations

236912

25
h-index

168376

53
g-index

61
all docs

61
docs citations

61
times ranked

8583
citing authors

#	ARTICLE	IF	CITATIONS
1	Repurposed Antiviral Drugs for Covid-19 – Interim WHO Solidarity Trial Results. <i>New England Journal of Medicine</i> , 2021, 384, 497-511.	27.0	2,014
2	Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 25018-25025.	7.1	279
3	Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. <i>Intensive Care Medicine</i> , 2017, 43, 1808-1819.	8.2	176
4	The Role of Complement in Liver Injury, Regeneration, and Transplantation. <i>Hepatology</i> , 2019, 70, 725-736.	7.3	123
5	Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 1261-1269.	3.9	84
6	Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. <i>Molecular Immunology</i> , 2017, 89, 10-21.	2.2	79
7	CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in <i>Escherichia coli</i> sepsis in pigs. <i>FASEB Journal</i> , 2010, 24, 712-722.	0.5	61
8	Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19. <i>Journal of Neurology</i> , 2021, 268, 3574-3583.	3.6	56
9	Double Blockade of CD14 and Complement C5 Abolishes the Cytokine Storm and Improves Morbidity and Survival in Polymicrobial Sepsis in Mice. <i>Journal of Immunology</i> , 2014, 192, 5324-5331.	0.8	52
10	Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. <i>Rheumatology</i> , 2016, 55, 1337-1339.	1.9	49
11	Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases – C3 or C5 emerge together with CD14 as promising targets. <i>Journal of Leukocyte Biology</i> , 2017, 101, 193-204.	3.3	49
12	Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. <i>Intensive Care Medicine</i> , 2019, 45, 1518-1539.	8.2	47
13	Combined Inhibition of Complement (C5) and CD14 Markedly Attenuates Inflammation, Thrombogenicity, and Hemodynamic Changes in Porcine Sepsis. <i>Journal of Immunology</i> , 2013, 191, 819-827.	0.8	41
14	<i>Ornithodoros moubata</i> Complement Inhibitor Is an Equally Effective C5 Inhibitor in Pigs and Humans. <i>Journal of Immunology</i> , 2011, 187, 4913-4919.	0.8	40
15	Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome. <i>Medicine (United States)</i> , 2017, 96, e6338.	1.0	40
16	Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations. <i>Journal of Internal Medicine</i> , 2022, 291, 801-812.	6.0	38
17	Diagnosis and outcome of acute respiratory failure in immunocompromised patients after bronchoscopy. <i>European Respiratory Journal</i> , 2019, 54, 1802442.	6.7	36
18	Bride and groom in systemic inflammation – The bells ring for complement and Toll in cooperation. <i>Immunobiology</i> , 2012, 217, 1047-1056.	1.9	35

#	ARTICLE	IF	CITATIONS
19	Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation. <i>Journal of Immunology</i> , 2013, 191, 4769-4777.	0.8	34
20	Combined inhibition of complement and CD14 improved outcome in porcine polymicrobial sepsis. <i>Critical Care</i> , 2015, 19, 415.	5.8	32
21	Elevated plasma sTIM-3 levels in patients with severe COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 92-98.	2.9	31
22	Systemic CD14 Inhibition Attenuates Organ Inflammation in Porcine Escherichia coli Sepsis. <i>Infection and Immunity</i> , 2013, 81, 3173-3181.	2.2	29
23	Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1221-1230.	10.7	29
24	Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock. <i>ESC Heart Failure</i> , 2018, 5, 292-301.	3.1	27
25	Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood. <i>Journal of Immunology</i> , 2019, 203, 1571-1578.	0.8	27
26	Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9. <i>Scientific Reports</i> , 2021, 11, 23205.	3.3	26
27	The Role of Bradykinin and the Effect of the Bradykinin Receptor Antagonist Icatibant in Porcine Sepsis. <i>Shock</i> , 2011, 36, 517-523.	2.1	25
28	IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction. <i>Frontiers in Immunology</i> , 2018, 9, 2035.	4.8	21
29	Influenza and associated co-infections in critically ill immunosuppressed patients. <i>Critical Care</i> , 2019, 23, 152.	5.8	21
30	Polyvalent immunoglobulin significantly attenuated the formation of IL-1 β in Escherichia coli-induced sepsis in pigs. <i>Immunobiology</i> , 2013, 218, 683-689.	1.9	19
31	Post challenge inhibition of C3 and CD14 attenuates Escherichia coli-induced inflammation in human whole blood. <i>Innate Immunity</i> , 2014, 20, 68-77.	2.4	17
32	Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses. <i>Molecular Immunology</i> , 2017, 89, 111-114.	2.2	17
33	Organ inflammation in porcine Escherichia coli sepsis is markedly attenuated by combined inhibition of C5 and CD14. <i>Immunobiology</i> , 2015, 220, 999-1005.	1.9	12
34	The use of antibiotics in the intensive care unit of a tertiary hospital in Malawi. <i>BMC Infectious Diseases</i> , 2020, 20, 776.	2.9	12
35	Respiratory Mechanics and Outcomes in Immunocompromised Patients With ARDS. <i>Chest</i> , 2020, 158, 1947-1957.	0.8	12
36	Selective inhibition of TNF- α or IL-1 β does not affect E. coli-induced inflammation in human whole blood. <i>Molecular Immunology</i> , 2010, 47, 1774-1782.	2.2	11

#	ARTICLE	IF	CITATIONS
37	Acute Respiratory Failure Outcomes in Patients with Hematologic Malignancies and Hematopoietic Cell Transplant: A Secondary Analysis of the EFRAIM Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 78.e1-78.e6.	1.2	9
38	Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial. <i>Journal of Internal Medicine</i> , 2022, 291, 241-243.	6.0	9
39	Acute respiratory failure in immunocompromised patients: outcome and clinical features according to neutropenia status. <i>Annals of Intensive Care</i> , 2020, 10, 146.	4.6	9
40	The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load. <i>Clinical and Experimental Immunology</i> , 2015, 181, 457-467.	2.6	8
41	Assessing the evidence on remdesivir. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1630-1631.	9.1	8
42	Combined Inhibition of C5 and CD14 Attenuates Systemic Inflammation in a Piglet Model of Meconium Aspiration Syndrome. <i>Neonatology</i> , 2018, 113, 322-330.	2.0	7
43	General anaesthesia related mortality in a limited resource settings region: a retrospective study in two teaching hospitals of Butembo. <i>BMC Anesthesiology</i> , 2021, 21, 60.	1.8	7
44	Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology. <i>Platelets</i> , 2022, 33, 640-644.	2.3	7
45	Reduced Cardiac Function by Echocardiography in a Minority of COVID-19 Patients 3 Months after Hospitalization. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 243-244.	2.8	6
46	Vitamin C, Hydrocortisone, and the Combination Thereof Significantly Inhibited Two of Nine Inflammatory Markers Induced by Escherichia Coli But Not by Staphylococcus Aureus " When Incubated in Human Whole Blood. <i>Shock</i> , 2022, 57, 72-80.	2.1	3
47	Etiologies and Outcomes of Acute Respiratory Failure in Solid Organ Transplant Recipients: Insight Into the EFRAIM Multicenter Cohort. <i>Transplantation Proceedings</i> , 2020, 52, 2980-2987.	0.6	2
48	Practice of standard monitoring during anaesthesia in hospitals of North Kivu: a survey of health facilities of the health antenna of Butembo. <i>BMC Health Services Research</i> , 2020, 20, 262.	2.2	2
49	Bacteremia in critically ill immunocompromised patients with acute hypoxic respiratory failure: A post-hoc analysis of a prospective multicenter multinational cohort. <i>Journal of Critical Care</i> , 2021, 64, 114-119.	2.2	2
50	Complement ratios C3bc/C3 and sC5b-9/C5 do not increase the sensitivity of detecting acute complement activation systemically. <i>Molecular Immunology</i> , 2022, 141, 273-279.	2.2	2
51	The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report. <i>BMC Infectious Diseases</i> , 2021, 21, 137.	2.9	1
52	Intraperitoneal microdialysis detects intestinal leakage earlier than hemodynamic surveillance and systemic inflammation in a pig model. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 219-227.	1.5	1
53	ICU-acquired pneumonia in immunosuppressed patients with acute hypoxemic respiratory failure: A post-hoc analysis of a prospective international cohort study. <i>Journal of Critical Care</i> , 2021, 63, 243-245.	2.2	0
54	The IL-6 receptor inhibitor tocilizumab attenuated expression of C5a receptor 1 and 2 in patients with myocardial infarction. <i>Molecular Immunology</i> , 2017, 89, 128.	2.2	0